Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1642 1644 1675
This examiner grants 64% of resolved cases
Lia Elan Taylor is an examiner in Tech Center 1600 and Art Unit 1641. The examiner has 191 resolved cases and an allowance rate of 64.4 percent. The interview lift is 29.4 percent, suggesting that verbal communication is a key factor in overcoming rejections and reaching an allowance. Practitioners should prioritize scheduling an interview to address any technical concerns raised during the examination process.
The median days to allowance is 1159. This duration reflects the typical prosecution cycle for the 191 cases handled by this examiner in Art Unit 1641. With a 64.4 percent allowance rate, applicants have a good chance of success. The 29.4 percent lift provided by examiner interviews is a significant tool for practitioners. The 1159-day median pendency provides a specific benchmark for applications in Tech Center 1600. These metrics define the prosecution experience for this docket.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19409123 | CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION | Final Rejection | GENENTECH, INC. |
| 18366061 | TRANSFERRIN RECEPTOR BINDING PROTEINS AND CONJUGATES | Non-Final OA | Eli Lilly and Company |
| 18462320 | METHOD OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18141728 | MASKED SINGLE-DOMAIN ANTIBODIES AND METHODS THEREOF | Final Rejection | Regents of the University of Minnesota |
| 18257409 | CONJUGATED FUMONISIN TO PROTECT AGAINST MYCOTOXICOSIS | Non-Final OA | INTERVET INC. |
| 18292586 | ENGINEERED IMMUNE CELL THAT SPECIFICALLY TARGETS MESOTHELIN AND USES THEREOF | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18285714 | THERAPEUTIC METHODS USING CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18106903 | TREATMENT OF AN ISCHEMIC HEART DISEASE | Final Rejection | Yeda Research and Development Co. Ltd. |
| 17771982 | ANTIBODIES FOR BINDING PLASMINOGEN | Final Rejection | Monash University |
| 17636425 | Anti-C7 Antibody Or Antibody Fragment | Final Rejection | University College Cardiff Consultants Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy